Haleon PLC Executes Share Buyback Program

An update from Haleon PLC Sponsored ADR ( (HLN) ) is now available.

On May 27, 2025, Haleon PLC announced the purchase and cancellation of 805,346 ordinary shares as part of its share buyback program initiated on March 28, 2025. This transaction impacts the company’s share capital, reducing the number of ordinary shares with voting rights to 9,004,451,602, which may influence shareholder notifications under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (HLN) stock is a Buy with a $13.40 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.

Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are built on innovation and deep human understanding.

Average Trading Volume: 14,661,907

Technical Sentiment Signal: Buy

Current Market Cap: $50.31B

For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.